Accepted for/Published in: JMIR Formative Research
Date Submitted: Jan 11, 2022
Open Peer Review Period: Jan 11, 2022 - Mar 8, 2022
Date Accepted: Apr 19, 2022
(closed for review but you can still tweet)
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Does a daily collagen peptide supplement reduce bloating in healthy female adults? – findings from a mixed method digital study.
ABSTRACT
Background:
The effect of dietary collagen on managing digestive symptoms is currently lacking in the literature.
Objective:
To gain a better understanding of this issue, we conducted a two-phase mixed methods study.
Methods:
Phase I was a qualitative study to explore current attitude and practice amongst consumers and healthcare practitioners. The findings were used to design an 8-week Phase II digital study called Gutme! conducted in the United States (US) in healthy female volunteers (BMI > 25kg/m2). Our aim was to determine whether an 8-week daily supplementation of 20g dietary collagen peptide supplement (Peptan©) would result in a reduction of common digestive symptoms. The study was a prospective, open-label, single arm, longitudinal design. Participation involved 2 weeks of baseline tracking (dietary, symptom, mood, stool and lifestyle) using an app, followed by 8 weeks of tracking and taking 20g collagen peptide supplement split into 2 dosages per day. Participants were required to complete an online symptom questionnaire at baseline, week 2 and 8 and participate in two scheduled video interviews.
Results:
Out of 40 recruited participants, 14 completed the study. Findings indicate that 93% of those who completed the study experienced a reduction in bloating and an improvement in other digestive symptoms.
Conclusions:
The use of a 20g daily collagen peptide supplement may reduce bloating and improve mild digestive symptoms in otherwise healthy female adults in the absence of any other dietary or lifestyle interventions. Clinical Trial: The study design was approved by the Integreview IRB an ethics advisory board (2329- Proofpilot) and was registered on clinicaltrial.gov (NCT04245254).
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.